Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2021 · 10-Q
Revenue$134.70M$134.70M+32.3% vs Q1 2020 Net Income-$4.13M-$4.13MN/M vs Q1 2020 EPS Diluted-$0.04-$0.04N/M vs Q1 2020 Gross Profit$108,310,000+40.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$17,780,000+808.5% Free Cash Flowderived$13,799,000N/M Margins · derivedGross margin80.4%+4.5 pt vs Q1 2020
Operating margin-0.1%+3.3 pt vs Q1 2020
Net margin-3.1%−6.9 pt vs Q1 2020
ended Mar 31, 2021 · filed Apr 29, 2021 · 29 d after period end